Icagen, based in Research Triangle Park, N.C., focuses on the discovery, development and commercialization of orally-administered, small-molecule drugs that modulate ion channel targets.
Pfizer previously owned 11 percent of Icagen and had invested about $56 million in the company.
Related Articles on Pfizer:
Pfizer Reports “Potentially Improper Payments” Made Outside U.S.
Global Pain Medication Sales Rise 8.9% Since 2005
Study: Lyrica Pain Drug From Pfizer Effective for Spinal Pain
